Literature DB >> 27480082

Inactivation of the LKB1-AMPK signaling pathway does not contribute to salivary gland tumor development - a short report.

Natascha Cidlinsky1, Giada Dogliotti1, Tobias Pukrop2, Rudolf Jung3, Florian Weber3, Michael P Krahn4.   

Abstract

PURPOSE: Activation of AMPK by the tumor suppressor LKB1 represents an essential gatekeeping step for cells under energetic stress to prevent their growth and proliferation by inhibiting mTOR activation, until the energy supply normalizes. The LKB1/AMPK pathway is frequently downregulated in various types of cancer, thereby uncoupling tumor cell growth and proliferation from energy supply. As yet, little information is available on the role of the LKB1/AMPK pathway in tumors derived from salivary gland tissues.
METHODS: We performed LKB1 protein expression and AMPK and mTOR activation analyses in several salivary gland tumor types and their respective healthy control tissues using immunohistochemistry.
RESULTS: No significant downregulation of LKB1 expression or decreased activation of AMPK or mTOR were observed in any of the salivary gland tumors tested. In contrast, we found that the salivary gland tumors exhibited an increased rather than a decreased AMPK activation. Although the PI3K/Akt pathway was found to be activated in most of the analyzed tumor samples, the unchanged robust activity of LKB1/AMPK likely prevents (over)activation of mTOR.
CONCLUSION: In contrast to many other types of cancer, inactivation or downregulation of the LKB1/AMPK pathway does not substantially contribute to the pathogenesis of salivary gland tumors.

Entities:  

Keywords:  AMPK; LKB1; PI3K-pathway; Salivary gland tumor; mTOR

Mesh:

Substances:

Year:  2016        PMID: 27480082     DOI: 10.1007/s13402-016-0290-8

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  48 in total

1.  World Health Organization classification of tumours: pathology and genetics of head and neck tumours.

Authors:  Lester Thompson
Journal:  Ear Nose Throat J       Date:  2006-02       Impact factor: 1.697

Review 2.  The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator.

Authors:  Brandon Faubert; Emma E Vincent; Maya C Poffenberger; Russell G Jones
Journal:  Cancer Lett       Date:  2014-01-28       Impact factor: 8.679

3.  Manipulation of tumor metabolism for therapeutic approaches: ovarian cancer-derived cell lines as a model system.

Authors:  Kristina Goetze; Christian G Fabian; Andrea Siebers; Livia Binz; Daniel Faber; Stefano Indraccolo; Giorgia Nardo; Ulrike G A Sattler; Wolfgang Mueller-Klieser
Journal:  Cell Oncol (Dordr)       Date:  2015-08-19       Impact factor: 6.730

4.  A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets.

Authors:  Andrew M Arsham; Jessica J Howell; M Celeste Simon
Journal:  J Biol Chem       Date:  2003-05-30       Impact factor: 5.157

5.  Could a possible crosstalk between AMPK and TGF-β signaling pathways be a key player in benign and malignant salivary gland tumors?.

Authors:  Nastaran M Ghahhari; Hamed M Ghahhari; Mehdi Kadivar
Journal:  Onkologie       Date:  2012-11-20

6.  The LKB1 tumor suppressor negatively regulates mTOR signaling.

Authors:  Reuben J Shaw; Nabeel Bardeesy; Brendan D Manning; Lyle Lopez; Monica Kosmatka; Ronald A DePinho; Lewis C Cantley
Journal:  Cancer Cell       Date:  2004-07       Impact factor: 31.743

7.  Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome.

Authors:  Michael N Corradetti; Ken Inoki; Nabeel Bardeesy; Ronald A DePinho; Kun-Liang Guan
Journal:  Genes Dev       Date:  2004-07-01       Impact factor: 11.361

8.  Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells.

Authors:  Toshiki Nakaoka; Akinobu Ota; Takayuki Ono; Sivasundaram Karnan; Hiroyuki Konishi; Akifumi Furuhashi; Yukinobu Ohmura; Yoichi Yamada; Yoshitaka Hosokawa; Yoshiaki Kazaoka
Journal:  Cell Oncol (Dordr)       Date:  2014-03-06       Impact factor: 6.730

9.  Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas.

Authors:  Cristina M Contreras; Sushma Gurumurthy; J Marshall Haynie; Lane J Shirley; Esra A Akbay; Shana N Wingo; John O Schorge; Russell R Broaddus; Kwok-Kin Wong; Nabeel Bardeesy; Diego H Castrillon
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

10.  Drosophila PATJ supports adherens junction stability by modulating Myosin light chain activity.

Authors:  Arnab Sen; Zsanett Nagy-Zsvér-Vadas; Michael P Krahn
Journal:  J Cell Biol       Date:  2012-11-05       Impact factor: 10.539

View more
  5 in total

1.  Silymarin and its active component silibinin act as novel therapeutic alternatives for salivary gland cancer by targeting the ERK1/2-Bim signaling cascade.

Authors:  Eun-Sun Choi; Sejun Oh; Boonsil Jang; Hyun-Ju Yu; Ji-Ae Shin; Nam-Pyo Cho; In-Hyoung Yang; Dong-Hoon Won; Hye-Jeong Kwon; Seong Doo Hong; Sung-Dae Cho
Journal:  Cell Oncol (Dordr)       Date:  2017-04-11       Impact factor: 6.730

2.  CDKN2A-p53 mediated antitumor effect of Lupeol in head and neck cancer.

Authors:  Sayantan Bhattacharyya; Vasanthakumar Sekar; Biswanath Majumder; Debapriya G Mehrotra; Samir Banerjee; Anup K Bhowmick; Neyaz Alam; Gautam K Mandal; Jaydip Biswas; Pradip K Majumder; Nabendu Murmu
Journal:  Cell Oncol (Dordr)       Date:  2016-12-30       Impact factor: 6.730

Review 3.  Controlling the master-upstream regulation of the tumor suppressor LKB1.

Authors:  Lars Kullmann; Michael P Krahn
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

4.  High Mobility Group Box 1 Protein in Osteoarthritic Knee Tissue and Chondrogenic Progenitor Cells: An Ex Vivo and In Vitro Study.

Authors:  Gunar Wagner; Christoph Lehmann; Christa Bode; Nicolai Miosge; Andrea Schubert
Journal:  Cartilage       Date:  2019-03-26       Impact factor: 4.634

5.  Membrane-binding and activation of LKB1 by phosphatidic acid is essential for development and tumour suppression.

Authors:  Giada Dogliotti; Lars Kullmann; Pratibha Dhumale; Christian Thiele; Olga Panichkina; Gudrun Mendl; Roland Houben; Sebastian Haferkamp; Andreas W Püschel; Michael P Krahn
Journal:  Nat Commun       Date:  2017-06-26       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.